Three new studies report genetic variants near IL28B, which encodes interferon-λ3 (interleukin 28B), are associated with response to treatment of chronic hepatitis C virus infection with interferon-alfa/ribavirin combination therapy. This renews interest in how interferons suppress viremia and could lead to improved clinical decisions for chronic HCV infection treatment based on individual genotype.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study
BMC Health Services Research Open Access 24 September 2014
-
Role of viral and host factors in interferon based therapy of hepatitis C virus infection
Virology Journal Open Access 01 October 2013
-
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
Journal of Gastroenterology Open Access 17 April 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
NIH Consensus. NIH Consens. State Sci. Statements 19, 1–46 (2002).
Shepard, C.W., Finelli, L. & Alter, M.J. Lancet Infect. Dis. 5, 558–567 (2005).
McHutchison, J.G. et al. N. Engl. J. Med. 361, 580–593 (2009).
Bowden, D.S. & Berzsenyi, M.D. Future Microbiol. 1, 103–112 (2006).
Suppiah, V. Nat. Genet. advance online publication, doi:10.1038/ng.447 (13 September 2009).
Tanaka, Y. Nat. Genet. advance online publication, doi:10.1038/ng.449 (13 September 2009).
Ge, D. et al. Nature advance online publication, doi:10.1038/nature08309 (16 August 2009).
Conjeevaram, H.S. et al. Gastroenterology 131, 470–477 (2006).
Kotenko, S.V. et al. Nat. Immunol. 4, 69–77 (2003).
Sheppard, P. et al. Nat. Immunol. 4, 63–68 (2003).
Marcello, T. et al. Gastroenterology 131, 1887–1898 (2006).
Robek, M.D., Boyd, B.S. & Chisari, F.V. J. Virol. 79, 3851–3854 (2005).
Sirén, J., Pirhonen, J., Julkunen, I. & Matikainen, S. J. Immunol. 174, 1932–1937 (2005).
Shiffman, M. et al. J. Hepatol. 50 (Suppl.) S237 (2009).
Kraft, P. et al. Nat. Rev. Genet. 10, 264–269 (2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O'Brien, T. Interferon-alfa, interferon-λ and hepatitis C. Nat Genet 41, 1048–1050 (2009). https://doi.org/10.1038/ng.453
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.453
This article is cited by
-
Incidence and cost of treatment-emergent comorbid events in insured patients with chronic hepatitis C virus infection: a retrospective cohort study
BMC Health Services Research (2014)
-
Ex vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/Ribavirin therapy in chronic hepatitis C patients
Journal of Gastroenterology (2014)
-
Role of viral and host factors in interferon based therapy of hepatitis C virus infection
Virology Journal (2013)
-
Novel therapies for hepatitis C — one pill fits all?
Nature Reviews Drug Discovery (2013)
-
Association of IL28B genotypes with metabolic profiles and viral clearance rate in chronic hepatitis C patients
Hepatology International (2013)